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Defects in TRPM7 channel function deregulate
thrombopoiesis through altered cellular Mg2þ
homeostasis and cytoskeletal architecture
Simon Stritt1,2, Paquita Nurden1,3, Remi Favier4,5, Marie Favier5,6,7,8, Silvia Ferioli9, Sanjeev K. Gotru1,2,
Judith M.M. van Eeuwijk1,2, Harald Schulze1, Alan T. Nurden3, Michele P. Lambert10,11, Ernest Turro12,13,14,15,
Stephanie Burger-Stritt16, Masayuki Matsushita17, Lorenz Mittermeier9, Paola Ballerini4, Susanna Zierler9,
Michael A. Laffan18,19, Vladimir Chubanov9, Thomas Gudermann9,20,21, Bernhard Nieswandt1,2 & Attila Braun1,2
Mg2þ plays a vital role in platelet function, but despite implications for life-threatening
conditions such as stroke or myocardial infarction, the mechanisms controlling [Mg2þ ]i in
megakaryocytes (MKs) and platelets are largely unknown. Transient receptor potential
melastatin-like 7 channel (TRPM7) is a ubiquitous, constitutively active cation channel with a
cytosolic a-kinase domain that is critical for embryonic development and cell survival. Here
we report that impaired channel function of TRPM7 in MKs causes macrothrombocytopenia
in mice (Trpm7ﬂ/ﬂ-Pf4Cre) and likely in several members of a human pedigree that, in addition,
suffer from atrial ﬁbrillation. The defect in platelet biogenesis is mainly caused by cytoskeletal
alterations resulting in impaired proplatelet formation by Trpm7ﬂ/ﬂ-Pf4Cre MKs, which is
rescued by Mg2þ supplementation or chemical inhibition of non-muscle myosin IIA heavy
chain activity. Collectively, our ﬁndings reveal that TRPM7 dysfunction may cause
macrothrombocytopenia in humans and mice.
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P
latelets are continuously produced from megakaryocytes
(MKs) in the bone marrow by a cytoskeleton-driven
process of which the molecular regulation is not fully
understood. MKs extend long cytoplasmic protrusions into bone
marrow sinusoids, where larger fragments, so-called preplatelets,
are shed and further divide within the circulation to give rise to
platelets (Supplementary Movie 1)1–3.
Transient receptor potential melastatin-like 7 (TRPM7)
channel and kinase domain, but not its kinase activity, are
critical for embryonic development4–6 and knockdown or
cell-speciﬁc TRPM7 knockout approaches give rise to
impaired cytoskeletal organization, cell migration, proliferation,
polarization and survival. These defects could partially be
explained by increased non-muscle myosin IIA heavy chain
(NMMIIA)-mediated contractility of the actin cytoskeleton5,7–13.
Of note, among other substrates, the kinase domain of TRPM7
phosphorylates annexin I and NMMIIA, thus interfering with
cell survival and cytoskeletal rearrangements14,15. Interestingly,
several variants of NMMIIA similarly altered the contractility
of the actomyosin complex in MKs, thereby interfering with
proplatelet formation in humans and mice16. During mega-
karyopoiesis, NMMIIA activity is suppressed by phosphorylation
of its C-terminus, enabling MK polyploidisation and ultimately
proplatelet formation17. However, for proper platelet ﬁssion and
sizing, NMMIIA needs to be re-activated under shear stress in the
circulation16,18. Although both kinase and channel activity of
TRPM7 have been proposed to regulate cytoskeletal dynamics,
channel activity alone was sufﬁcient to restore cell polarization,
morphology and migration10,13,19, suggesting a critical role of
cations therein. Consequently, the differential role of TRPM7
channel versus kinase activity in the regulation of the
cytoskeleton still remains unclear. Moreover, TRPM7 has been
implicated as a key regulator of signal conductance in the murine
heart by regulating the expression of different pacemaker
channels, such as HCN4 (ref. 20). Although TRPM7-mediated
cation inﬂux has been detected in MKs (ref. 21), its role in
thrombopoiesis has not been investigated to date.
Here we report that impaired channel function but not kinase
activity of TRPM7 in MKs causes macrothrombocytopenia
in Trpm7ﬂ/ﬂ-Pf4Cre mice and likely in several members of a
human pedigree, which, in addition, feature atrial ﬁbrillation.
The impaired proplatelet formation is associated with cytoskeletal
alterations due to increased actomyosin contractility and can be
rescued by either Mg2þ supplementation or chemical inhibition
of NMMIIA activity. Collectively, our ﬁndings reveal TRPM7
dysfunction as a novel cause of macrothrombocytopenia in mice
and potentially in humans too.
Results
Defects in TRPM7 cause macrothrombocytopenia. We
identiﬁed TRPM7 as the key Mg2þ channel and magnesium
transporter 1 (MagT1) to be expressed in murine platelets
(Supplementary Fig. 1a) and generated MK- and
platelet-speciﬁc TRPM7 knockout mice (Supplementary
Fig. 1b,c). The absence of TRPM7 currents in patch clamp
measurements conﬁrmed the efﬁcacy of the targeting strategy
in primary bone marrow MKs (Supplementary Fig. 1d).
Unexpectedly, these mice displayed a macrothrombocytopenia
(Fig. 1a,b) with enlarged and spherical platelets, often containing
large vacuoles as revealed by electron microscopy (Fig. 1c).
In contrast, mice carrying a kinase-dead K1646R mutation
in Trpm7 (ref. 6; Trpm7KI) showed normal platelet counts, size
and morphology, thus suggesting that the lack of TRPM7 channel
function rather than its kinase activity accounts for the
macrothrombocytopenia in the mutant mice (Supplementary
Fig. 2a–e). In line with this notion, intracellular Mg2þ
concentrations in Trpm7ﬂ/ﬂ-Pf4Cre platelets, but not in Trpm7KI
platelets, were decreased (Fig. 1d; Supplementary Fig. 2f)6.
Impaired proplatelet formation causes thrombocytopenia.
A mildly reduced platelet lifespan in Trpm7ﬂ/ﬂ-Pf4Cre mice
(t½¼ 43.6 h for wild type (WT) versus t½¼ 35.7 h for
Trpm7ﬂ/ﬂ-Pf4Cre mice), however, was insufﬁcient to explain the
reduced platelet count and was not associated with altered
platelet terminal galactose levels (Supplementary Fig. 3a,b).
Immunostaining of whole-femora bone marrow sections (Fig. 2a)
revealed an increased number of MKs in the mutant mice
(6.3±0.3 for WT versus 13.3±1.6 for Trpm7ﬂ/ﬂ-Pf4Cre mice;
Fig. 2b). The MKs in Trpm7ﬂ/ﬂ-Pf4Cre mice were also located
further from bone marrow sinusoids than in controls (Fig. 2c)
suggesting impaired migration of MK-precursors to bone
marrow sinusoids. Although splenomegaly was not observed in
Trpm7ﬂ/ﬂ-Pf4Cre mice, we found an increased number of MKs in
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Figure 1 | TRPM7 deﬁciency causes mild macrothrombocytopenia in mice. Moderately reduced peripheral platelet counts (a) and signiﬁcantly increased
platelet volume (b) were quantiﬁed with an automated cell analyser. Values are mean±s.d. (n¼ 7). (c) Transmission electron microscopy (TEM) analysis
shows discoid WTplatelets, but enlarged and round resting platelets of Trpm7ﬂ/ﬂ-Pf4Cre mice. V, vacuole. Scale bar, 1mm. (d) Total platelet cation content was
determined by inductively coupled plasma mass spectrometry. Values are mean±s.d. (n¼ 5). Unpaired Student’s t-test; ***Po0.001; **Po0.01; *Po0.05.
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an expanded red pulp in the spleen and in line with the increased
MK numbers, plasma thrombopoietin levels were decreased, thus
further indicating deregulated megakaryopoiesis (Supplementary
Fig. 4a–d).
In contrast to a previous report on a neuroblastoma cell line22,
the formation of podosomes, F-actin rich structures that are
thought to serve cell migration and proplatelet protrusion23, was
unaltered in Trpm7ﬂ/ﬂ-Pf4Cre MKs (Supplementary Fig. 5a)
suggesting that other defects must account for their more
distant localization from bone marrow sinusoids (Fig. 2c).
Interestingly, mutant MKs displayed an increased mean ploidy
as compared with controls (16.9 N±1.6 N in controls versus
22.4 N±3.4 N for Trpm7ﬂ/ﬂ-Pf4Cre mice; Fig. 2d) thus excluding
impaired MK maturation as the cause of thrombocytopenia.
Despite the increased ploidy in vivo, we found a decreased
proplatelet formation for both foetal liver- (Fig. 2e) and bone
marrow-derived (Supplementary Fig. 5b) Trpm7ﬂ/ﬂ-Pf4Cre
MKs in vitro. This was further conﬁrmed in vivo by intravital
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Figure 2 | Cytoskeletal alterations account for the macrothrombocytopenia. (a) Confocal microscopy images of immunostained bone marrow sections.
Scale bars, 50mm (left panel. Scale bars, 15 mm (right panel). MKs, proplatelets and platelets are identiﬁed by GPIb staining (green). Endoglin staining (red)
labels vessels; 40 ,6-diamidino-2-phenylindole (DAPI) stains nuclei (blue). (b) Quantiﬁcation of bone marrow MKs per visual ﬁeld (328 246 mm). Values
are mean±s.d. (n¼ 6; each 20 visual ﬁelds were analysed). (c) MK localization was quantiﬁed as their distance from bone marrow sinusoids. Values are
mean±s.d. (n¼6; 300 MKs). Wilcoxon–Mann–Whitney test; ***Po0.001. (d) Mean ploidy of primary bone marrow MKs. Values are mean±s.d. (n¼6).
(e) Percentage of proplatelet-forming foetal liver-derived MKs in vitro on day 4 of culture. Values are mean±s.d. (n¼ 7). (f) Intravital two-photon
microscopy of bone marrow MKs in the skulls of WT and Trpm7ﬂ/ﬂ-Pf4Cre mice. Arrow shows a normal sized proplatelet in a WT bone marrow sinusoid
(PPF); dashed arrow indicates bulky proplatelet in the sinus of a mutant mouse (BPF). Rhodamine dextran labels vessels (red) and anti-GPIX antibodies
label MKs and platelets (green). Scale bars, 25 mm. (g) Quantiﬁcation of proplatelet formation in vivo by intravital two-photon microscopy. Proplatelet
formation was quantiﬁed during a period of 13 h (27 movies each 30min duration) in WT and 6.5 h (13 movies each 30min duration) in Trpm7ﬂ/ﬂ-Pf4Cre
mice and normalized to the cell number per visual observed ﬁeld. Values are mean±s.d. (n¼ 12 versus 6). (h) Confocal microscopy of in vitro cultured
foetal liver-derived MKs revealed an increased content of microtubules in rarely found and less branched proplatelets of Trpm7ﬂ/ﬂ-Pf4Cre MKs. a-tubulin
(green) and F-actin (red) stain the cytoskeleton. DAPI, blue. Scale bar, 25mm. (i,j) Transmission electron microscopy (TEM) analysis of bone marrow MKs.
Trpm7ﬂ/ﬂ-Pf4Cre MKs display an irregular distribution of granules, tortuous membranes (i) and proplatelet structure (j). EC, endothelial cell; VS, vascular
sinusoid; RBC, red blood cell. Scale bars, 2.5mm. All images are representative of at least ﬁve animals. Unpaired Student’s t-test (if not stated otherwise);
***Po0.001; **Po0.01.
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two-photon microscopy of the bone marrow (0.88%min 1
±0.16%min 1 of WT MKs formed proplatelets versus
0.23%min 1±0.12%min 1 of Trpm7ﬂ/ﬂ-Pf4Cre MKs), which
revealed that Trpm7ﬂ/ﬂ-Pf4Cre MKs preferentially formed short
and bulky proplatelet protrusions (0.85%min 1±0.13%min 1
of observed MKs in Trpm7ﬂ/ﬂ-Pf4Cre mice versus
0.05%min 1±0.04%min 1 in WT mice) that remained
attached to the cell body during the observation period
(Fig. 2f,g; Supplementary Movies 1–3).
The actin and microtubule cytoskeleton are critical for proper
proplatelet formation2. We therefore analysed the cytoskeletal
architecture of Trpm7ﬂ/ﬂ-Pf4Cre MKs and found an increased
content and aberrant organization of microtubules in
proplatelet-forming, resting and spread MKs (Fig. 2h;
Supplementary Fig. 6a–c). In support of this, extraction of the
microtubule cytoskeleton of resting bone marrow-derived MKs
by ultracentrifugation revealed an increased microtubule content
in the Triton X100 insoluble pellet fraction (Supplementary
Fig. 6d,e). Of note, increased microtubule stability is
associated with post-translational modiﬁcations of a-tubulin
that include detyrosination (Glu-tub) and acetylation (ac-tub)
which could account for the increased number of microtubules in
Trpm7ﬂ/ﬂ-Pf4Cre MKs (ref. 24). Nonetheless, we found an
increased prevalence of highly dynamic tyrosinated (Tyr)
microtubules as evidenced by lower Glu-/Tyr- (2.5±0.3
for control versus 1.5±0.2 for Trpm7ﬂ/ﬂ-Pf4Cre MKs) and
ac-/Tyr-tubulin ratios (2.2±0.2 for control versus 1.6±0.2 for
samples of Trpm7ﬂ/ﬂ-Pf4Cre mice), suggesting that accelerated
microtubule assembly/dynamics accounted for the observed
alterations (Supplementary Fig. 6d–g). Moreover, in line with
the critical role of microtubules in trafﬁcking of intracellular
cargo, electron microscopy revealed a non-homogeneous
distribution of granules, tortuous membrane complexes
and aberrantly sized proplatelets in mutant MKs (Fig. 2i;
Supplementary Fig. 7). Furthermore, we found thick and
densely packed proplatelets in bone marrow sinusoids with
signs of apoptosis reﬂecting impaired proplatelet fragmentation
and release of preplatelets from Trpm7ﬂ/ﬂ-Pf4Cre MKs (Fig. 2f,j;
Supplementary Movies 2 and 3). In line with the impaired
proplatelet formation (Fig. 2e,g; Supplementary Fig. 5b and
Supplementary Movies 2 and 3), the recovery of the platelet count
after antibody-induced platelet depletion was slightly delayed in
Trpm7ﬂ/ﬂ-Pf4Cre mice (Supplementary Fig. 8). The pronounced
increase above initial platelet counts might be attributed to
the increased number of MKs in Trpm7ﬂ/ﬂ-Pf4Cre mice and
alternative platelet release mechanisms as recently shown by
Nishimura et al.25.
Altered NMMIIA activity impairs proplatelet formation.
NMMIIA has been described as a downstream effector of TRPM7
kinase14,22 and importantly, abnormal function of NMMIIA has
been associated with impaired formation and fragmentation of
proplatelets in humans and mice16. Moreover, Mg2þ was
recently shown to modify NMMIIA activity by regulating
ADP release and its afﬁnity to actin ﬁlaments, thus further
linking TPRM7 channel to NMMIIA function26. Strikingly,
analysis of NMMIIA localization in MKs on whole-bone-
marrow sections in situ revealed a homogeneous distribution in
the cell body of control (92.1±2.0% in WT versus 14.7±1.1% in
Trpm7ﬂ/ﬂ-Pf4Cre mice), while it predominated in the cell cortex
of Trpm7ﬂ/ﬂ-Pf4Cre MKs (0.4±0.8% in WT versus 48.1±3.6% in
Trpm7ﬂ/ﬂ-Pf4Cre mice; Fig. 3a,b). A similar distribution pattern
was found in vitro for foetal liver-derived MKs where in addition
a signiﬁcant accumulation of NMMIIA in proplatelets of mature
WT MKs was observed (Fig. 3c). Moreover, NMMIIA localization
was also altered in Trpm7ﬂ/ﬂ-Pf4Cre platelets. However, in contrast
to MKs, NMMIIA predominated in the cell cortex of WT
platelets reminiscent of the marginal band, whereas it was
homogeneously distributed in platelets of Trpm7ﬂ/ﬂ-Pf4Cre mice
(Supplementary Fig. 9a–c). This observation is in line with a
report on resting foreskin ﬁbroblasts in which NMMIIA and
a-tubulin staining overlapped extensively at the cell cortex under
resting, non-contractile conditions. However, on induction of cell
migration and activation of NMMIIA, the overlap of NMMIIA
and a-tubulin staining decreased, allowing NMMIIA to exert its
contractile effects on the actin cytoskeleton27. To further analyse
the cause of the absent NMMIIA staining and the altered
localization to the cell cortex in Trpm7ﬂ/ﬂ-Pf4Cre MKs in situ, we
next allowed bone marrow-derived MKs to spread on a
collagen type I-coated surface. Surprisingly, on spreading of
Trpm7ﬂ/ﬂ-Pf4Cre MKs (Fig. 3d,e) or platelets (Supplementary
Fig. 10a–d) we found a rapid degradation of NMMIIA that
could be rescued by pretreatment with the NMMIIA
inhibitor blebbistatin or by Mg2þ supplementation (Fig. 3e–g;
Supplementary Fig. 10e–h). Based on these ﬁndings we speculated
that deregulated [Mg2þ ]i in Trpm7ﬂ/ﬂ-Pf4Cre cells may cause
an increased activity of NMMIIA resulting in its rapid
degradation on cell stimulation. In agreement with the
increased co-localization of NMMIIA to actin ﬁlaments in
resting Trpm7ﬂ/ﬂ-Pf4Cre platelets (Supplementary Fig. 9),
sedimentation of cross-linked actin ﬁlaments of resting platelets
revealed an increased amount of NMMIIA in the pellet fraction
(Supplementary Fig. 11a–c). On activation, NMMIIA efﬁciently
cross-linked actin ﬁlaments and accumulated in the pellet
fraction of WT platelets (Supplementary Fig. 11d–f). In sharp
contrast, we found a marked reduction in NMMIIA on
stimulation of Trpm7ﬂ/ﬂ-Pf4Cre platelets (Supplementary
Fig. 11d–f), similar to the ﬁndings in spread MKs (Fig. 3c) or
platelets (Supplementary Fig. 10a–d). To exclude that the
observed effects were due to the short observation period, bone
marrow-derived MKs were cultured for 48 h in the presence of
collagen types I or IV, two major components of the extracellular
matrix in the bone marrow. Strikingly, we found a reduced
content of NMMIIA in Trpm7ﬂ/ﬂ-Pf4Cre MKs (reduction of
39.9±10.3% for collagen I and 76.9±14.5% for collagen IV)
cultured in the presence of different collagens as compared with
control cells (Fig. 3h; Supplementary Fig. 12a,b). Together these
results suggested an increased NMMIIA activity under resting
conditions and that NMMIIA undergoes a rapid degradation on
stimulation of platelets and MKs from Trpm7ﬂ/ﬂ-Pf4Cre mice thus
allowing proplatelet formation and cell spreading.
Deregulated [Mg2þ ]i perturbs NMMIIA activity. We
hypothesized that deregulated Mg2þ homeostasis26 and increased
NMMIIA activity may account for the impaired proplatelet
formation in Trpm7ﬂ/ﬂ-Pf4Cre MKs (refs 16,26). In support of
this, either inhibition of NMMIIA activity or Mg2þ
supplementation could almost fully restore proplatelet formation
of Trpm7ﬂ/ﬂ-Pf4Cre MKs in vitro (Fig. 4a,b). Of note, while
pretreatment of foetal liver- (Fig. 4c) or bone marrow-derived MKs
(Supplementary Fig. 13) with the Ca2þ chelators 1,2-bis
(2-aminophenoxy) ethane-N,N,N0,N0-tetraacetic acid tetrakis
(acetoxymethyl ester) (BAPTA-AM) or ethylene glycol tetraacetic
acid (EGTA) did not exert gross effects; non-speciﬁc chelation of
Ca2þ and Mg2þ with ethylenediaminetetraacetic acid (EDTA)
signiﬁcantly reduced proplatelet formation by MKs, suggesting that
Mg2þ is critical for this process28,29. According to a previous
report8, Mg2þ supplementation should restore [Mg2þ ]i in mutant
MKs, which cannot be fully achieved through an upregulation of
MagT1 expression under normal culture conditions (Fig. 4d,e).
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Inhibition of NMMIIA restores cytoskeletal architecture.
Besides increasing cortical tension through relaxation of
the underlying cytoskeleton17,30, blebbistatin treatment reduced
the prevalence and stability of microtubules in proplatelet
protrusions, as evidenced by decreased Glu-/Tyr- (1.1±0.1 for
WT and 1.3±0.1 for samples of Trpm7ﬂ/ﬂ-Pf4Cre mice) and ac-/
Tyr-tubulin ratios (1.3±0.1 for WT and 1.2±0.2 for samples of
Trpm7ﬂ/ﬂ-Pf4Cre mice; Supplementary Fig. 14). Immunostaining
(Fig. 5a–c) and electron microscopy (Fig. 5d) revealed an
increased number of aberrantly organized microtubules in
Trpm7ﬂ/ﬂ-Pf4Cre platelets as compared with controls, similar to
ﬁndings in mutant MKs. This correlated with an increased
presence of highly dynamic Tyr-tubulin (151.4±3.7% of controls;
Fig. 5e–g), leading to accelerated and uncontrolled microtubule
polymerization in mutant cells (Fig. 5a,h). Stable microtubules
in Trpm7ﬂ/ﬂ-Pf4Cre platelets displayed a similar pattern of
post-translational modiﬁcations of a-tubulin (104.2±14.2% of
control for Glu-, and 97.4±9.4% of control for ac-tubulin) and
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and 2nd ab). All images are representative of at least ﬁve animals. Unpaired Student’s t-test; ***,###Po0.001; **Po0.01.
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were efﬁciently disassembled on cold challenge, thus excluding
enhanced stability as cause for the increased microtubule
content (Fig. 5e–h). Interestingly, pretreatment of WT platelets
with EDTA, but not EGTA, BAPTA-AM or MgCl2, mimicked
these cytoskeletal alterations (Fig. 6a–c), changes that could also
be reverted by blebbistatin (Fig. 6d–f), thus further supporting the
notion that reduced [Mg2þ ]i alters the subcellular localization
and activity of NMMIIA resulting in cytoskeletal disorganization.
In agreement with this, we observed an increased content of
ﬁlamentous actin in resting Trpm7ﬂ/ﬂ-Pf4Cre platelets
(Supplementary Fig. 15a,b) and a decreased polymerization of
ﬁlamentous actin on platelet activation (Fig. 6g; Supplementary
Fig. 15b,c). Moreover, spread Trpm7ﬂ/ﬂ-Pf4Cre platelets displayed
an increased surface area (Fig. 6h; Supplementary Fig. 16) most
likely reﬂecting the activation-dependent rapid degradation of
NMMIIA and consequently the loss of coherent cytoplasmic
contractile forces normally generated by activated NMMIIA
(refs 31,32).
Variants in TRPM7 may cause macrothrombocytopenia. We
next hypothesized that some DNA variants of extreme low-fre-
quency affecting TRPM7 channel function might also cause
macrothrombocytopenia in humans. Examining the results of
genome sequencing of 702 cases with bleeding and platelet dis-
orders of unknown genetic basis in the BRIDGE database of the
NIHR BioResource—Rare Diseases revealed three cases with a
coding variant unobserved in nearly 81,000 control DNA sam-
ples: UCN 0012 with p.C721G (c.2161T4G), UCN 0025 with
p.R902C (c.2704C4T) variant, and UCN 0110 with p.G1353D
(c.4058G4A; Supplementary Table 1). Two of these three index
cases (p.C721G and p.R902C) showed low-platelet counts and
macrothrombocytopenia. Interestingly, the variant of index
patient UCN 0110 (p.G1353D (c.4058G4A)) was
located close to the a-kinase domain and the absence of
macrothrombocytopenia is in agreement with the results on the
Trpm7KI mice (Supplementary Table 1 and Supplementary
Fig. 2). Unfortunately, the family with the p.R902C variant was
unavailable for further studies.
Further studies were focussed on the index case UCN 0012
with a p.C721G (c.2161T4G) variant and pedigree members.
Sanger sequencing showed that the p.C721G variant was present
in two further pedigree members with macrothrombocytopenia,
but was absent in one asymptomatic pedigree member, indicating
segregation with the TRPM7 genotype (Fig. 7a, Supplementary
Table 2 and Supplementary Fig. 17). For the fourth patient
(pedigree member 2), now deceased, macrothrombocytopenia
was detected during her life (Fig. 7a). All other blood cell
parameters and platelet function were normal for all
p.C721G patients. Strikingly, paroxysmal atrial ﬁbrillation was
also present for the index case (pedigree member 5) and her
mother (pedigree member 2).
Similarly to Trpm7ﬂ/ﬂ-Pf4Cre mouse platelets, we found a
reduced content of Mg2þ and an increased concentration of
Ca2þ in platelets from all tested patients with the p.C721G
substitution as compared with healthy controls (Fig. 7b). Patch
clamp studies on HEK293 cells conﬁrmed that the p.C721G
variant reduced TRPM7 channel activity by 85±4% as compared
with WT controls (Fig. 7c) despite being localized to the cell
membrane (Supplementary Fig. 18). Likewise, in vitro studies on
the p.R902C variant revealed, although less pronounced, a
reduced TRPM7 channel activity by 39±6% (Supplementary
Fig. 19). Platelets from all tested patients displayed an increased
size, with a spherical shape and contained numerous
vacuoles. Moreover, while platelets from controls displayed the
typical discoid shape and microtubules organized into coils, the
marginal band, platelets from the p.C721G patients showed an
aberrant distribution of granules and an increased number and
anarchic organization of microtubules (Fig. 7d; Supplementary
Fig. 20). The abnormal cytoskeletal organization could be
conﬁrmed by immunostaining on resting p.C721G platelets
(Fig. 7e,f; Supplementary Figs 21 and 22) and similarly to the
Trpm7ﬂ/ﬂ-Pf4Cre platelets, which was not associated with increased
microtubule stability (Fig. 7g; Supplementary Fig. 21).
Altered regulation of NMMIIA in p.C721G platelets. Since
the ultrastructure of human platelets from individuals carrying
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the p.C721G variant strongly resembled that of Trpm7ﬂ/ﬂ-Pf4Cre
mouse platelets, we next analysed the distribution and stability of
NMMIIA. Whereas in control platelets NMMIIA localized to the
marginal band, it was homogeneously distributed throughout the
cytoplasm of platelets from the patients (Fig. 8a,b; Supplementary
Fig. 22). In line with the observations on Trpm7ﬂ/ﬂ-Pf4Cre mouse
platelets, spread platelets from the patients showed an increased
surface area, a strong decrease in NMMIIA and an increased
content of microtubules (Fig. 8c,d; Supplementary Figs 23
and 24). As for the mouse model, blebbistatin prevented loss of
NMMIIA on spreading (Fig. 8d,e; Supplementary Fig. 25) and
rescued the cytoskeletal organization of resting platelets after cold
challenge (Fig. 8f,g; Supplementary Fig. 26). As mentioned above,
patients 2 and 5 suffered from atrial ﬁbrillation which might be
associated with alterations in [Mg2þ ]i (ref. 33). Furthermore, lack
of TRPM7 has been associated with altered expression of
channels, such as HCN4 encoding the pacemaker current in the
conduction system of the heart that has also previously been
linked to atrial ﬁbrillation20,34.
Discussion
In the present study, we provide evidence that defects in TRPM7
channel function cause macrothrombocytopenia in mice and
likely in humans too. These results demonstrate a critical role of
TRPM7-mediated Mg2þ inﬂux in regulating NMMIIA
activity and cytoskeletal rearrangements during thrombopoiesis.
In support of this, it has been shown that Mg2þ inhibits
NMMIIA activity by reducing the ADP release rate and its afﬁnity
for actin26. Furthermore, using Trpm7KI mice (Supplementary
Fig. 2), we convincingly show that these effects occur
independently of TRPM7 a-kinase activity. However, it is too
early to exclude that the kinase domain also acts as a molecular
hub orchestrating yet unknown signalling events, and thereby
contributes to the development of macrothrombocytopenia.
The observed loss of NMMIIA in Trpm7ﬂ/ﬂ-Pf4Cre bone marrow
MKs in situ and in vitro on spreading could represent a
physiological process to overcome the inhibitory effects of
increased NMMIIA activity enabling proplatelet formation
(Fig. 3a,b,d–h; Supplementary Figs 10–12). In support of this
hypothesis, NMMIIA degradation was most pronounced on
culture of bone marrow-derived MKs on collagen type IV, which
predominates in the vascular niche where proplatelet formation
occurs (Fig. 3a,b,h; Supplementary Fig. 12). Furthermore, using
different antibodies and experimental approaches, we provide
several independent lines of evidence that the observed loss of
NMMIIA on activation or spreading of TRPM7-deﬁcient cells
represents protein degradation. However, it is important to note
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that we cannot entirely exclude epitope masking due to
modiﬁcations on NMMIIA (Figs 3 and 8; Supplementary
Figs 10–12 and 23–25).
It has recently been reported that plasma Thpo levels are also
regulated via Ashwell–Morell receptor-dependent clearance of
desialylated platelets, which in turn triggers expression of Thpo in
hepatocytes and thus regulates platelet production35. However, it
is important to note that in agreement with the moderately
reduced platelet lifespan, we did not observe differences in
platelet terminal galactose levels suggesting that the decreased
plasma Thpo levels are reciprocally associated to the increased
number of MKs in the bone marrow and spleen (Fig. 2a,b;
Supplementary Figs 3 and 4)36. Furthermore, the marked increase
in platelet counts after immuno-depletion might result from an
alternative platelet release mechanism as recently described by
Nishimura et al.25.
The here-described human disorder (Fig. 7; Supplementary
Tables 1 and 2) is clearly distinguishable from MYH9-related
platelet disease, which can be associated with hearing
loss, cataracts or renal failure37. However, patients with variants
in TRPM7 and MYH9 both display macrothrombocytopenia
with more spherical platelets and partially, increased actomyosin
contractility (Figs 7 and 8; Supplementary Figs 21–26)16.
The different clinical outcomes and symptoms of patients
with different genetic variants of TRPM7 are most likely
due to the location and functional consequences of the
mutations (Supplementary Table 1). While both the p.C721G
and the p.R902C variant are located in the channel domain
and reduce channel activity (Fig. 7c and Supplementary Fig. 19),
the p.G1353D variant is not located within the channel
domain which may likely explain the distinct phenotype and
absence of macrothrombocytopenia in the index patient UCN
0025. Similar genotype–phenotype-relationships have been
observed for patients suffering from MYH9-related
disorder38,39, Wiskott–Aldrich syndrome2,40 or ﬁlaminopathy
A41. Although we could not observe a dominant negative effect
of the p.C721G variant on TRPM7 channel function in vitro,
we speculate that the defect might be masked by the high-
expression levels of TRPM7 in the used system or diminished
channel activity may not represent the only mechanistic
explanation for the observed phenotypes. Furthermore,
Trpm7þ / mice did not display macrothrombocytopenia
suggesting that gene haploinsufﬁciency does not account for the
observed disease (Supplementary Fig. 27). However, the impaired
channel activity and the striking phenotypic similarities in
platelets from patients and Trpm7ﬂ/ﬂ-Pf4Cre mice strongly
suggest that the variants in TRPM7 account for the observed
macrothrombocytopenia.
a b
c
Pl
at
el
et
s
w
ith
a
be
rra
n
tM
T 
(%
)
0
20
40
60
80
100
***
***
M
T 
su
rfa
ce
(μm
2 )
0
2
4
6
*** ***
Untr. 1 2.5 2.5 5 1 2.5 1 2.5
EGTA BAPTA MgCl2 EDTA
(mM) (μM) (mM)
W
T
Tr
pm
7
fl/
fl-
Pf
4C
re
4–37 °C + blebbi
α-tub F-act
d
WT
Trpm7 fl/fl-Pf4Cre
0
0.5
1.0
1.5
2.0
2.5
M
FI
 (P
ha
l.-F
ITC
a
ct
./r
es
t.) 
(a.
u.
)
10/1 0.01
RhdA + U Thr
0.11
CRP
*** *** ***
***
g
h
e
M
T 
su
rfa
ce
(μm
2 )
0
1.0
2.0
3.0 *
f
Untr. Blebbi
Pl
at
el
et
s
w
ith
a
be
rra
n
tM
T 
(%
)
0
20
40
60
80 ***
*
R
el
. s
pr
ea
d
a
re
a
pe
r p
la
te
le
t(%
) ###
0
40
80
120
160
WT, 4–37 °C 
Un
tre
at
ed
BA
PT
A 
(μM
)
M
gC
l 2 
(m
M)
EG
TA
 (m
M)
ED
TA
 (m
M)
1.0 2.5
2.5 5.0
1.0 2.5
1.0 2.5
Ø Ø
α-tub F-act
Trpm7 fl/fl-Pf4Cre
Resting
+ 25 μM blebbi
WT
##
Figure 6 | Deregulated [Mg2þ ]i accounts for the altered cytoskeletal organization. (a) Resting control platelets were incubated for 3 h at 4 C in
Tyrode’s-HEPES buffer supplemented with the indicated reagents. After rewarming to 37 C platelets were ﬁxed, allowed to adhere to PLL-coated coverslips
and were stained for a-tubulin (green) and F-actin (red). (b,c) Quantiﬁcation of microtubule (MT) morphology (b) and surface (c) revealed that decreasing
[Mg2þ ]i (EDTA) but not [Ca2þ ]i (EGTA or BAPTA) in WTplatelets reproduces the cytoskeletal alterations found in Trpm7ﬂ/ﬂ-Pf4Cre platelets. Values are
mean±s.d. (n¼ 5; 200 platelets). (d–f) Rewarming of chilled and blebbistatin-pretreated (25mM) Trpm7ﬂ/ﬂ-Pf4Cre platelets restored cytoskeletal
organization. Scale bars, 3mm. Values are mean±s.d. (n¼6; 200 platelets). (g) The ratio of polymerized actin in activated versus resting platelets was
determined. Platelet stimulation was achieved using AþU, 10mM ADP and 1mM U46619; Thr, 0.01Uml 1 thrombin; CRP, 1mgml 1 collagen-related
peptide; Rhd, 0.1 mgml 1 rhodocytin. Values are mean±s.d. (n¼ 6). (h) The relative spread surface area of untreated or blebbistatin-treated (25 mM)
platelets was determined using F-actin staining as a measure. Values are mean±s.d. (n¼ 6; 200 platelets). All images are representative of at least ﬁve
animals. Unpaired Student’s t-test; ***,###Po0.001; ##oPo0.01; *Po0.05.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms11097
8 NATURE COMMUNICATIONS | 7:11097 | DOI: 10.1038/ncomms11097 | www.nature.com/naturecommunications
Our study provides for the ﬁrst time several independent lines
of evidence that proper regulation of Mg2þ homeostasis in MKs
by TRPM7 plays a critical role in thrombopoiesis and platelet
sizing, both in humans and mice. Collectively, our results
highlight the clinical need to carefully control platelet count
and size in patients with deregulated Mg2þ homeostasis.
Ultimately, our ﬁndings suggest, after careful consideration and
assessment of adverse events, that Mg2þ supplementation may
be used as a potential treatment of patients with increased activity
of NMMIIA to manage thrombocytopenia. Despite the possibility
of severe potential side effects in patients with impaired kidney
function, Mg2þ supplementation is considered as a relatively safe
therapeutic intervention42–44. Nevertheless, further studies in
animal models and patients are required to assess the efﬁcacy and
safety of Mg2þ supplementation in the management of certain
cases of thrombocytopenia.
Finally, the fact that two of the patients in our study also
suffered from paroxysmal atrial ﬁbrillation promotes TRPM7 as a
novel candidate interfering with conductance in cardiac cells.
Methods
Semi-quantitative reverse transcription PCR. Total platelet RNA was isolated
after lysis using TRIzol reagent (15596018, Invitrogen) and tissue RNA was gained
using the Qiagen RNeasy kit. To generate cDNA 1 mg RNA was reverse transcribed
with the SuperScript II reverse transcriptase (18064014, Invitrogen) according to
the manufacturer’s instructions. b-actin transcripts were determined as control.
Primers used for the ampliﬁcation of Mg2þ transporters and channels are listed in
Supplementary Table 3.
Mice. Conditional Trpm7-deﬁcient mice were generated by intercrossing
Trpm7ﬂ/ﬂ mice (exon 17 ﬂanked by loxP sites) with mice carrying the
Cre-recombinase under the platelet factor 4 (Pf4) promoter45 (Supplementary
Fig. 1b). Trpm7ﬂ/ﬂ mice were described earlier4, Pf4-Cre mice were kindly provided
by Dr Radek Skoda and Trpm7KI mice were generously provided by Dr Masayuki
Matsushita6. All mice used in experiments were 12- to 16-week-old and
sex-matched, if not stated otherwise. For experiments on MKs, only male
animals were used. All animal experiments were approved by the district
government of Lower Franconia (Bezirksregierung Unterfranken). Trpm7ﬂ/ﬂ-Pf4Cre
mice were genotyped via PCR on genomic DNA extracted from ear biopsies
using the following primer pair: Trpm7KO-F: 50-gaggtactggcaattgtgagc-30 and
Trpm7KO-R: 50-accacaaaatctctgccctct-30 yielding a 1,200-bp product for the
ﬂoxed, 1000 bp product for the WT and a 400-bp fragment for the recombined
allele (Supplementary Fig. 1c). For all experiments, the respective Trpm7ﬂ/ﬂ
(for Trpm7ﬂ/ﬂ-Pf4Cre mice) or Trpm7WT/WT (for Trpm7KI/KI mice) littermate
controls were used. All mice were derived from the following breeding strategies
for Trpm7ﬂ/ﬂ X Trpm7ﬂ/ﬂ-Pf4Cre, yielding 50% Trpm7ﬂ/ﬂ WT and 50%
Trpm7ﬂ/ﬂ-Pf4Cre mice or Trpm7WT/KI X Trpm7WT/KI resulting in 25%
Trpm7WT/WT, 50% Trpm7WT/KI and 25% Trpm7KI/KI mice, respectively.
Platelet preparation. Mice were bled under isoﬂurane anaesthesia. Blood was
collected in heparin (20Uml 1, Ratiopharm) and centrifuged twice for 6min at
300 g. Platelet-rich plasma (PRP) was supplemented with 2 ml ml 1 of apyrase
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(0.02Uml 1; A6410, Sigma-Aldrich) and 5 ml ml 1 prostacyclin I2 (PGI2)
(0.1mgml 1; P6188, Sigma-Aldrich) and platelets were pelleted by centrifugation
for 5min at 800 g, washed twice with Tyrodes-N-2-hydroxyethyl-piperazine-N02-
ethanesulfonic acid (HEPES) buffer (134mM NaCl, 0.34mM Na2HPO4, 2.9mM
KCl, 12mM NaHCO3, 5mM HEPES, 5mM glucose, 0.35% bovine serum albumin
(BSA), pH 7.4) containing 2 ml ml 1 apyrase and 5 ml ml 1 PGI2.
Blood samples of patients were obtained after informed consent in accordance
with the Declaration of Helsinki. Ethical approval was obtained from Inserm RBM
04–14 for the project ‘Network on the inherited diseases of platelet function and
platelet production’ and by the Ethics Committee of the University Hospital
Wu¨rzburg. Fresh blood samples of patients and healthy volunteers were collected
in 1/10 volume of acid-citrate-dextrose and centrifuged for 10min at 200 g. PRP
was collected, supplemented with 2 ml of apyrase (0.02Uml 1, Sigma-Aldrich)
and 5 ml PGI2 (0.1 mgml 1, Sigma-Aldrich) per ml PRP. Before adherence to
poly-L-lysine (PLL)-coated slides or spreading on different matrices, platelets
were pelleted by centrifugation for 10min at 800 g and washed twice with
Tyrodes-HEPES buffer containing 2 ml ml 1 apyrase and 5 ml ml 1 PGI2. The
samples were allowed to rest for 30min at 37 C prior to being used in experiments.
Flow cytometry. Diluted blood (1:20) was incubated for 15min at room
temperature (RT) with ﬂuorophore-conjugated antibodies (2 mgml 1) directed
against platelet surface glycoproteins. Platelet count and size (FSC) were assessed
using a FACSCalibur (BD Biosciences) ﬂow cytometer or with an automated blood
cell analyser (Sysmex KX-21N).
Transmission electron microscopy of platelets. To analyse platelet ultrastructure,
washed platelets were ﬁxed with 2.5% glutaraldehyde (16,210, Electron Microscopy
Sciences) in 50mM cacodylate buffer (12,201, pH 7.2; AppliChem). After embedding
in epon 812 (14,900, Electron Microscopy Sciences), ultrathin sections were gener-
ated and stained with 2% uranyl acetate (22,400, Electron Microscopy Sciences) and
lead citrate (17,800, Electron Microscopy Sciences). Samples were visualized with an
EM900 transmission electron microscope (Carl Zeiss).
Immunostaining on resting or spread platelets. Coverslips were either coated
with PLL (Sigma-Aldrich), ﬁbrinogen (100 mgml 1; F4883, Sigma-Aldrich) or
collagen-related peptide (CRP) (ref. 46; 6 mgml 1) overnight at 4 C. For
spreading on ﬁbrinogen, platelets were stimulated with 0.01Uml 1 thrombin
(10602400001, Roche) and allowed to spread for the indicated time. If indicated,
platelets were pre-incubated with toxins interfering with cytoskeletal dynamics
such as colchicine (10 mM; A4082, AppliChem) before the spreading assay. After
the indicated time points, platelets were either ﬁxed with 4% paraformaldehyde
(PFA) in PBS and analysed or processed for immunoﬂuorescence staining of the
cytoskeleton. Therefore, platelets were ﬁxed and permeabilized in PHEM buffer
(60mM piperazine-N,N-bis-2- ethanesulfonic acid, 25mM HEPES), 10mM
EGTA, 2mM MgCl2, pH 6.9) supplemented with 4% PFA and 1% IGEPAL CA-
630, stained with anti-a-tubulin-Alexa F488 (3.33 mgml 1, 322588 (B-5-1-2),
Invitrogen), anti-NMMIIA (10 mgml 1, #3403, polyclonal, CellSignaling) and
phalloidin-Atto647N (170 nM, 65906, Fluka) and mounted with Fluoroshield
(F6182, Sigma-Aldrich). All used ﬂuorophore-conjugated secondary antibodies
were purchased from Invitrogen. Samples were visualized using a Leica TCS SP5
confocal microscope (Leica Microsystems).
Inductively coupled plasma mass spectrometry (ICP-MS). The cation content
of 4 107 platelets was analysed by ICP-MS on platelets from PRP. ICP-MS
analysis was performed by ALS Scandinavia AB (Lulea, Sweden).
Determination of platelet lifespan. The clearance of platelets from the circula-
tion was determined by the retro-orbital injection of 5 mg DyLight 488-labelled
anti-GPIX antibody2,47 in PBS into male mice. The percentage of labelled platelets
was determined by daily blood withdrawal and subsequent analysis by ﬂow
cytometry using ﬂuorophore-conjugated platelet-speciﬁc antibodies2.
Immunoﬂuorescence staining on whole-femora cryosections. Femora of male
mice were isolated, ﬁxed with 4% paraformaldehyde (A3813, AppliChem) and
5mM sucrose (S0389, Sigma-Aldrich), transferred into 10% sucrose in PBS and
dehydrated using a graded sucrose series. Subsequently the samples were embedded
in Cryo-Gel (39475237, Leica Biosystems) and shock frozen in liquid nitrogen.
Frozen samples were stored at  80 C. Cryosections (7-mm-thick) were generated
using the CryoJane tape transfer system (Leica Biosystems) and probed with
Alexa488-conjugated anti-glycoprotein (GP) Ib (ref. 48) antibodies (7A9,
1.33 mgml 1), to speciﬁcally label platelets and MKs, and Alexa647-conjugated
anti-CD105 antibodies (3.33 mgml 1, 120402 (MJ7/18), Biolegend) to stain the
endothelium. Nuclei were stained using 40,6-diamidino-2-phenylindole
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Figure 8 | Altered NMMIIA activity accounts for the aberrant cytoskeletal organization. (a) Poly-L-lysine-immobilised resting platelets were
permeabilized and stained for F-actin (red) a-tubulin (green), NMMIIA (cyan) and analysed by confocal microscopy. (b) Image analysis revealed an altered
distribution of NMMIIA in platelets from patients with variants in TRPM7 as compared with healthy controls. Box plots display ﬁrst and third quartiles and
whiskers mark minimum and maximum values unless exceeding 1.5 interquartile range (IQR) of at least 70 platelets; symbols represent outliers and the
horizontal line displays median (n¼ 3 controls versus patient 3). Wilcoxon–Mann–Whitney test; ***Po0.001 (c–e) Degradation of NMMIIA on spreading
of platelets from patient 3 (c,d) could be prevented by blebbistatin pretreatment (d,e). Values are mean±s.d. (n¼ 3; 200 platelets). (f,g) Pretreatment of
resting platelets from patient 3 with 25mM blebbistatin restored cytoskeletal organization on cold challenge with subsequent rewarming (f), which was
further evidenced by a signiﬁcantly decreased surface covered by microtubules (MT) per platelet (g). Values are mean±s.d. (n¼ 3; 200 platelets).
Unpaired Student’s t-test (if not stated otherwise); ***,###Po0.001; *Po0.05.
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(1mgml 1, D1306, Invitrogen). Samples were visualized with a Leica TCS SP5
confocal microscope (Leica Microsystems).
Histology. Sections (3-mm-thick) of formalin-ﬁxed parafﬁn embedded spleens and
femora of male mice were prepared deparafﬁnized and stained with haematoxylin
(MHS32, Sigma-Aldrich) and eosin (318906, Sigma-Aldrich). MK number,
morphology and localization were analysed with an inverted Leica DMI 4000 B
microscope.
In vitro differentiation and cultivation of bone marrow MKs. Haematopoietic
stem cells were isolated from male mouse bone marrow single-cell suspensions
using a magnetic bead-based negative depletion kit (anti-rat-IgG Dynabeads,
Invitrogen) in combination with rat-anti-mouse antibodies directed against
CD45R/B220, TER-119, CD3, Ly-6G/C and CD11b (each 0.5 mg per 107 cells,
103216 (RA3-6B2), 116214 (TER-119), 100208 (17A2), 108414 (RB6-8C5) and
101214 (M1/70), Biolegend). Experiments were performed according to the
manufacturer’s protocol. Cells were cultured in MK-medium supplemented with
50mgml 1 recombinant hirudin (Schering) at 37 C, 5% CO2 for 3 days, before
MK enrichment using a two step BSA density gradient. On day 4, the percentage of
proplatelet-forming MKs was determined using a light microscope (Zeiss).
MK spreading. In vitro cultivated bone marrow MKs of male mice were allowed to
adhere and spread at 37 C and 5% CO2 on coverslips coated with ﬁbrillar collagen
type I (50 mgml 1; Nycomed), ﬁbrinogen (100 mgml 1; F4883, Sigma-Aldrich) or
CRP (6mgml 1) for the indicated time. MK spreading was stopped by ﬁxation and
permeabilization of the cells using PHEM buffer supplemented with 4% PFA and
1% IGEPAL CA-630.
Immunoﬂuorescence staining of cultured or spread MKs. To visualize the
cytoskeleton, the cultured MKs were spun onto glass slides (Shandon Cytospin 4,
Thermo Scientiﬁc), ﬁxed and permeabilized in PHEM buffer supplemented with
4% PFA and 1% IGEPAL CA-630 and blocked with 1% BSA in PBS. F-actin was
stained using phalloidin-Atto647N (170 nM, 65906, Fluka) and tubulin was stained
with an anti-a-tubulin-Alexa F488 (3.33 mgml 1, 322588 (B-5-1-2), Invitrogen)
antibody. WASp (10 mgml 1, #4860, CellSignaling) or NMMIIA (10 mgml 1,
#3403, polyclonal, CellSignaling) staining served as podosome marker. Nuclei were
stained using 40,6-diamidino-2-phenylindole (1 mg ml 1, D1306, Invitrogen) before
mounting of samples with Fluoroshield (F6182, Sigma-Aldrich). Visualization was
performed with a Leica TCS SP5 confocal microscope (Leica Microsystems).
Determination of MK ploidy. To determine bone marrow MK ploidy, both femora
of male mice were isolated and the bone marrow was ﬂushed and homogenized.
Non-speciﬁc binding sites of the 5D7 antibody were blocked by incubation of the cell
suspension with 0.02mgml 1 anti-FcgR antibody (553142 (2.4G2), BD Pharmin-
gen). Afterwards, MKs were stained using a ﬂuorescein isothiocyanate-conjugated
anti-CD41 antibody (10mgml 1, 5D7). Finally, cells were ﬁxed, permeabilized and
DNA was stained using 50mgml 1 propidium iodide (P3561, Invitrogen) staining
solution with 100mgml 1 RNaseA (EN0202, Fermentas) in PBS. Analysis was
performed by ﬂow cytometry and FlowJo software (Tree Star Inc.).
Plasma thrombopoietin levels. Plasma Thpo levels were determined using the
Mouse Thrombopoietin Quantikine ELISA Kit (DY488, R&D Systems). Brieﬂy,
plasma was collected, diluted (1:5 in Reagent Diluent) and immediately applied as
duplicates onto the anti-Thpo-IgG coated 96-well plate and incubated for 2 h at
room temperature. The plate was washed ﬁve times and incubated for 2 h with
100ml of horseradish peroxidase-conjugated anti-mouse Thpo antibodies. After
another ﬁve washing steps, tetramethylbenzidine solution was added and incubated
for 30min at room temperature. The reaction was aborted by the addition of 100 ml
of diluted hydrochloric acid. Optical densities of the samples were determined
using a Multiskan Ascent (96/384) plate reader (MTX Lab Systems) at 450 nm.
Wavelength correction was performed at 570 nm.
In vitro differentiation of foetal liver-derived MKs. The livers of 13.5–14.5-day-
old female and male mouse foetuses were isolated from time-mated female mice
and single-cell suspensions were prepared in MK-medium (IMDM medium
containing 10% FCS, 1% penicillin/streptomycin (31980097, Gibco) and
50 ngml 1 recombinant Thpo (ref. 49). The homogenized foetal liver cells were
cultured for 72 h at 37 C and 5% CO2 and mature MKs were enriched on day three
of culturing using a BSA density gradient (3% and 1.5% BSA in PBS; A7030,
Sigma-Aldrich). If indicated the cells were treated with 25 mM blebbistatin (B0560,
Sigma-Aldrich) or maintained in culture medium supplemented with 10mM
MgCl2. On day 4, the percentage of proplatelet-forming MKs was determined by
counting the total number of MKs as well as the number of proplatelet-forming
MKs under a light microscope (Zeiss).
Two-photon intravital microscopy of the bone marrow. Male and female mice
were anaesthetized and a 1-cm incision was made along the midline to expose the
frontoparietal skull while carefully avoiding damage to the bone tissue. The mouse
was placed on a customized metal stage equipped with a stereotactic holder to
immobilize its head2,3. Bone marrow vasculature was visualized by injection of
tetramethylrhodamine dextran (8 mg per g body weight, 2MDa, Molecular Probes).
Platelets and MKs were antibody-stained (0.6 mg per g body weight anti-GPIX-
Alexa Fluor 488). Images were acquired with a ﬂuorescence microscope equipped
with a  20 water objective with a numerical aperture of 0.95 and a TriM Scope II
multiphoton system (LaVision BioTec), controlled by ImSpector Pro-V380
software (LaVision BioTec). Emission was detected with HQ535/50-nm and
ET605/70-nm ﬁlters. A tuneable broad-band Ti:Sa laser (Chameleon, Coherent)
was used at 760 nm to capture Alexa Fluor 488 and rhodamine dextran
ﬂuorescence. ImageJ software (NIH) was used to generate movies.
Transmission electron microscopy of bone marrow MKs. For transmission
electron microscopy of MKs, bone marrow was ﬂushed from 12- to 16-week-old
male mice using Karnovsky ﬁxative (2% PFA, 2.5% glutaraldehyde in 0.1M
cacodylate buffer) and incubated overnight at 4 C. Subsequently, fatty components
of the samples were ﬁxed with 2% osmium tetroxide in 50mM sodium cacodylate
(pH 7.2), stained with 0.5% aqueous uranyl acetate, dehydrated with a graded
ethanol series and embedded in Epon 812. Ultrathin sections were stained with 2%
uranyl acetate (in 100% ethanol) followed by lead citrate. Images were taken on a
EM900 transmission electron microscope (Zeiss).
Platelet depletion. Circulating platelets were depleted in mice by injection of
20 mg per 30 g body weight anti-GPIba-antibodies (Emfret, Eibelstadt, Germany)
and platelet counts were monitored by ﬂow cytometry for 10 days.
Immunoblot. Denatured resting or convulxin-stimulated (0.5 mgml 1) platelets or
untreated and MgCl2 supplemented MKs were lysed and separated by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS–PAGE) and blotted onto
polyvinylidene diﬂuoride membranes. NMMIIA (1 mgml 1, #3403, polyclonal,
CellSignaling; 1 mgml 1, MP3791; ECM Biosciences), Gapdh (1mgml 1, G5262,
Sigma-Aldrich) or MagT1 (10 mgml 1, AP5056a, Abgent) were probed with the
respective antibodies and detected using horseradish peroxidase-conjugated sec-
ondary antibodies (0.33mgml 1) and enhanced chemiluminescence solution (JM-
K820-500, MoBiTec). Images were recorded using a MultiImage II FC Light
Cabinet (Alpha Innotech cooperation) device. Uncropped immunoblotting images
are shown in Supplementary Figs 28 and 29.
Extraction and sedimentation of the cytoskeleton. Resting or activated
(0.1 Uml 1 thrombin (10602400001, Roche) platelets (5.7 107) or MKs
(5 106) were lysed in PHEM buffer containing 1% Triton X100, 6 mM taxol
(A4667, AppliChem) for microtubule sedimentation or 2 mM phalloidin (A1488,
AppliChem) for F/G-actin sedimentation and protease inhibitors (P8340,
Sigma-Aldrich). Polymerized and soluble fractions were separated by centrifuga-
tion for 30min at 100.000 g (microtubules) or 16.000 g (F/G-actin), respectively,
and 37 C in a TLA-100 rotor (Beckman Coulter). Total platelet lysates, soluble
supernatants (S) and insoluble pellets (P) were supplemented with SDS–PAGE
buffer containing 5% b-mercaptoethanol (M6250, Sigma-Aldrich). Samples were
separated by SDS–PAGE, blotted onto polyvinylidene diﬂuoride membranes and
probed with anti-Tyr-tubulin (0.5 mgml 1, MAB1864 (YL1/2), Milipore), anti-
acetylated tubulin (1 mgml 1, sc-23950 (6-11B-1), Santa Cruz Biotechnology Inc.),
anti-detyrosinated-tubulin (1 mgml 1, AB3201, Milipore), NMMIIA (1 mgml 1,
#3403, polyclonal, CellSignaling; 1 mgml 1, MP3791; ECM Biosciences) or b-actin
(1 mgml 1, SAB5500001 (SP124), Milipore) antibodies.
Cold-induced microtubule disassembly. Microtubules were depolymerized by
incubation of platelets at 4 C; reassembly was allowed by subsequent rewarming at
37 C. Samples maintained at 4 C and 37 C as well as rewarmed platelets were
ﬁxed and permeabilized in PHEM buffer supplemented with 4% PFA and 1%
IGEPAL CA-630 and allowed to adhere to a PLL-coated coverslips. Samples were
immunostained using an anti-b1-tubulin (2.5 mgml 1, T4026, clone TUB 2.1,
Sigma-Aldrich) or anti-a-tubulin Alexa F488 antibody (3.33 mgml 1, 322588
(B-5-1-2), Invitrogen) and visualized using a Leica TCS SP5 confocal microscope
(Leica Microsystems).
Actin polymerization. Washed platelets were incubated with a DyLight-649–
labelled anti-GPIX antibody derivative (20 mgml 1). Subsequently, platelets were
either left unstimulated or were stimulated with the indicated agonists for 2min.
Platelets were ﬁxed with 0.55 volume of 10% paraformaldehyde in PHEM buffer
and treated with 0.1 volume 1% Triton X100. Subsequently, platelets were stained
with 10mM phalloidin-ﬂuorescein isothiocyanate (P5282, Sigma-Aldrich) for
30min and analysed on a FACSCalibur.
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Recruitment of patients. The index case and pedigree members were enrolled to
the French ‘Network on the inherited diseases of platelet function and platelet
production’ (INSERM RBM 01–14). Further subjects with bleeding and platelet
disorders (BPD) and with unrelated rare disorders (control data) were enrolled to
the BRIDGE-BPD project of the NIHR BioResource—Rare Diseases study
(UK REC 13/EE/0325). Here, gene variants were retained in an analysis set if they
occur at a frequency of o1:10,000 in the exome aggregation consortium
database based on over 60,000 individuals (http://exac.broadinstitute.org/). All
cases provided informed written consent at enrolment.
The BRIDGE bleeding and platelet disorders collection. We searched for cases
with coding variants of extreme low frequency in the TPRM7 gene by analysing
data from 702 index cases with BPDs of unknown genetic basis recruited to the
BRIDGE study of the NIHR BioResource—Rare Diseases. Gene variants were
identiﬁed in genome sequencing data by comparison with reference human
genome build GRCh37 and consequences were predicted using the Ensembl ver-
sion 75 TPRM7 transcript ENST00000313478. Variants predicted to alter the
amino acid sequence of the protein were retained in the analysis set if they
occurred at frequencies of o1 in 10,000 out of 67,000 individuals of the Exome
Aggregation Consortium (ExAC) database, o1 in 1,000 in the 10,000 subjects of
UK10K database ando1 in 100 in 3,453 subjects with unrelated rare disorders or
unaffected pedigree members recruited to other branches of the NIHR BioR-
esource. We selected cases with extreme low-frequency variants and on the basis of
clinical and laboratory characteristics, which were coded using Human Phenotype
Ontology (HPO) terms50 retrieved from the BRIDGE-BPD study database. We
then focused our further exploration on the cases with extremely rare variants that
were unobserved in the nearly 81,000 control DNA samples. The ﬁrst step was to
contact the families to explain the necessity to control these results by performing
co-segregation studies. One family met these requirements and additional family
members were examined in Paris at a French Centre for inherited platelet diseases.
Co-segregation studies. Genomic DNA from peripheral blood mononuclear cells
was extracted using a commercial DNA puriﬁcation kit (Qiagen) and exon 17 of
TRPM7 was ampliﬁed by polymerase chain reaction using the respective primer
pairs: TRPM7_Ex17_forw: 50-ggagaatgtgctctggattc-30 and TRPM7_Ex17_rev:
50-gccaatcatccatcttgctc-30 , expected product size 606 bp. PCR products were
puriﬁed with the help of QIAquick PCR puriﬁcation kit (Qiagen) and processed for
Sanger sequencing.
Platelet function testing. Platelet function testing of human blood was performed
by light transmission turbidometric aggregometry. To this end, PRP (2.5 105
platelet perml) was isolated and stimulated with different concentrations of agonists
(ADP, 5 and 10mM; collagen I, 1 and 5mgml 1; epinephrine, 5mM; arachidonic
acid, 1mM; ristocetin, 0.6 and 1.5mgml 1; and TRAP (thrombin receptor
activating peptide), 20mM). Light transmission was followed over time with PPP
set as 100% light transmission.
Transient expression of WT and p.C721G TRPM7 variants. The TRPM7
p.C721G and p.R902C variants were generated by site-directed mutagenesis on the
pcDNA3.1-TRPM7 expression construct51 using the QuickChange II XL site-
directed mutagenesis kit (200517, Agilent Technologies) with the following primer
pairs: Trpm7_C721G_for: 50-ctggagtaattcaaccggcctcaagttagcgtttc-30 and
Trpm7_C721G_rev: 50-gaaactgctaacttgaggccggttgaattactccag-30. The mutation was
conﬁrmed by sequencing. For transient expression of WT TRPM7 and the
p.C721G variant, human embryonic kidney (HEK) 293 cells were maintained at
37 C and 5% CO2 in Earle’s minimal essential medium supplemented with 10%
foetal bovine serum, 100mgml 1 streptomycin and 100Uml 1 penicillin
(Invitrogen). Cells were transiently co-transfected with eukaryotic expression
vectors encoding WT TRPM7 or the p.C721G and p.R902C variant with 100 ng of
an enhanced green ﬂuorescent protein (EGFP) reporter construct (pcDNA3.1)
using Lipofectamine2000 (Invitrogen) according to the manufacturer’s instructions
and processed for patch clamp measurements or confocal microscopy.
Electrophysiology. Patch clamp experiments were performed at a whole-cell
conﬁguration. Currents were elicited by a ramp protocol from  100 to þ 100mV
over 50ms acquired at 0.5Hz and a holding potential of 0mV. Inward currents
were extracted at  80mV, outward currents at þ 80mV and plotted versus time.
Data were normalized to cell size as pA pF 1. Capacitance was measured using the
automated capacitance cancellation function of the EPC10 (HEKA). Nominally
Mg2þ -free extracellular solution contained 140mM NaCl, 3mM CaCl2, 2.8mM
KCl, 0mM MgCl2, 10mM HEPES-NaOH, 11mM glucose (pH 7.2, 300mOsm).
Intracellular solution contained 120mM Cs-glutamate, 8mM NaCl, 1mM MgCl2,
10mM HEPES, 10mM BAPTA, 5mM EDTA (pH 7.2, 300mOsm).
Image analysis. All images of an experiment were acquired with the same laser
power, scan speed, detector settings, processed equally and analysed blinded.
Microtubule surface area was determined with the help of Fiji52 by thresholding the
a-tubulin staining of platelets and MKs using the same settings for both groups.
NMMIIA distribution in resting platelets was analysed on three-dimensional
surface plots and proﬁle plots with the help of Fiji52. Means of the ﬁrst and last
maxima and the mean between the ﬁrst and last minima of the histograms were
determined and the NMMIIAmax to NMMIIAmin was calculated and depicted.
NMMIIA distribution in spread MKs was analysed by grouping and counting the
different distribution patterns. The surface of spread platelets was measured by
thresholding the F-actin staining. To analyse the distribution/content of NMMIIA
in spread platelets the area of the NMMIIA staining was correlated to the total cell
size (F-actin) staining.
Data analysis. The presented results are mean±s.d. from at least three
independent experiments per group, if not otherwise stated. Data distribution
was analysed using the Shapiro–Wilk test and differences between control
and knockout mice were statistically analysed using Student’s t-test or
Wilcoxon–Mann–Whitney test, respectively. P-valueso0.05 were considered
as statistically signiﬁcant *Po0.05; **Po0.01; ***Po0.001. Results with a
P value40.05 were considered as not signiﬁcant (NS).
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